Trials / Completed
CompletedNCT04594928
A Study Evaluating the Effects of GLPG3667 Given as an Oral Treatment for 4 Weeks in Adults With Moderate to Severe Plaque Psoriasis
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GLPG3667 in Subjects With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Galapagos NV · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of GLPG3667 in multiple daily oral doses in subjects with moderate to severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GLPG3667 | GLPG3667 capsules |
| DRUG | Placebo | Matching placebo capsules |
Timeline
- Start date
- 2020-10-19
- Primary completion
- 2021-05-04
- Completion
- 2021-05-04
- First posted
- 2020-10-20
- Last updated
- 2021-05-27
Locations
7 sites across 3 countries: Bulgaria, Poland, Slovakia
Source: ClinicalTrials.gov record NCT04594928. Inclusion in this directory is not an endorsement.